Prevention & care

Neonatal jaundice: bilirubin, timing, measurement, treatment thresholds and evidence limits

10 sources · Latest source check 2026-10-20 UTC

On this page

Neonatal jaundice is yellowing of a newborn’s skin or eyes associated with bilirubin buildup. It is common and often settles, but timing, feeding, illness and the bilirubin result change its significance. Visible yellowing alone cannot establish the blood level or the underlying cause.[1]

Separate appearance, cause, duration and measurement

Separate appearance, cause, duration and measurement
Term or test	What it means	Interpretation limit
Visible jaundice	Yellowing of skin or eyes	Appearance can be harder to recognize on darker skin[1]
Hyperbilirubinemia	An increased bilirubin level	A measured value needs age and clinical context[3]
Hemolytic disease	Accelerated red-cell breakdown, including antibody-mediated disease	A cause of jaundice rather than a synonym for all newborn jaundice[7]
Prolonged or conjugated jaundice	Persistence or a different bilirubin fraction	Can require assessment beyond routine early jaundice[2]

Common does not mean every presentation is routine

The NHS describes bilirubin as a waste product normally removed by the liver and notes that newborn jaundice can also accompany infection, blood-group differences or liver problems. Its UK guidance treats jaundice within the first 24 hours, poor feeding, unusual sleepiness and breathing difficulty as concerning presentations. Dark urine or pale stools are also reasons for assessment. These features explain why a common condition still has important exceptions. A general description cannot diagnose an individual newborn or justify waiting for a routine check when the baby is unwell.[1]

Early and prolonged jaundice ask different clinical questions

NICE covers newborns under 28 days, including premature infants. It distinguishes jaundice in the first day from later jaundice, and includes assessment of persistent jaundice and conjugated bilirubin. The latter can point toward liver disease rather than only the usual early unconjugated bilirubin pattern. Its recommendations also warn that pigmentation changes may be harder to see on darker skin. The 2023 update and the guideline’s earlier evidence base should be retained together: a content update does not mean every threshold was derived from a new trial.[2]

The AAP chart is an age-specific clinical tool

The 2022 AAP guideline applies to infants born at least 35 weeks and interprets bilirubin using age in hours, gestational age and neurotoxicity risk factors. Treatment thresholds were raised modestly from earlier guidance, but the authors state that evidence does not permit exact thresholds to be derived solely from quantitative benefit–risk estimates. The charts combine evidence with expert judgment. They were not designed for every resource setting or infants below 35 weeks. This guide therefore explains threshold context without supplying a universal cutoff or a self-directed treatment chart.[3]

Gestational age and additional risks must not be conflated

The AAP’s implementation FAQ clarifies that gestational age is already represented in its different curves; additional neurotoxicity risk factors change the choice of chart. It also discusses follow-up, clinical judgment and selected circumstances for intravenous immunoglobulin. This is an explanation of how a professional guideline is interpreted, not an instruction that all risk factors trigger identical testing or therapy. The FAQ’s July 2025 update is distinct from the guideline’s 2022 publication. Care decisions still need the baby’s actual clinical findings and the locally applicable pathway.[4]

Stopping phototherapy and finishing follow-up are separate decisions

Bilirubin can rise again after phototherapy stops, so the team may plan another measurement. NHS Greater Glasgow and Clyde’s postnatal-ward guidance allows a planned recheck without necessarily remaining in hospital, with clear arrangements and community communication where appropriate. Ask when and where the recheck will happen and who will act on the result. Follow the baby’s actual care plan: gestation, age and clinical findings matter, and this guide supplies no treatment threshold.[9]

Home phototherapy means a supervised clinical service

Phototherapy uses special blue light for jaundice. In Kingston’s home service, the neonatal team selects and oversees care, nurses teach use of the supplied blanket, visit for blood tests and review the baby with hospital doctors. The team decides whether treatment continues and checks again after it stops. This illustrates organized home care, not a treatment anyone can start by obtaining a light. Availability and eligibility are local.[10]

Evidence & uncertainty

Measuring bilirubin through the skin before discharge probably reduces jaundice-related readmissions compared with visual inspection in one randomized study. That evidence does not establish a clear reduction in rare brain injury or validate a single treatment threshold for every newborn.[5]

Selected-source overview · Independent review pending

Published questions

Why does jaundice in the first 24 hours matter?

Selected-source overview · Independent review pending. Read the evidence context.

The NHS treats first-day jaundice as a concerning presentation requiring its emergency pathway. Timing can signal a cause beyond routine newborn bilirubin buildup; visible appearance alone is insufficient.[1]

Evidence behind this answer

Jaundice in babies
agency condition explanation · 2026
Selected original official page passages inspected; not an independent clinical appraisal · Appearance, bilirubin, causes, darker-skin recognition and UK urgent/emergency pathways